Nov 19, 2015 8:00am EST Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program
Nov 11, 2015 5:45pm EST Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2015
Nov 06, 2015 8:00am EST Pieris Pharmaceuticals Presents Data at SITC Conference on Lead Immuno-Oncology Program Demonstrating Selective Tumor-Targeted Immune Responses
Nov 05, 2015 9:00am EST Pieris Pharmaceuticals Announces Presentation of Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (ASH) Annual Meeting
Oct 29, 2015 8:30am EDT Pieris Pharmaceuticals to Host Third Quarter 2015 Investor Call on November 12th
Sep 30, 2015 7:30am EDT Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team
Sep 21, 2015 7:43am EDT Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program
Sep 15, 2015 8:30am EDT Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference
Sep 03, 2015 9:00am EDT Pieris Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9th at 3:50 pm EDT
